Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.8 USD | -2.26% | -8.11% | -24.15% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.15% | 230M | |
+11.07% | 227B | |
+15.13% | 198B | |
+17.96% | 142B | |
+31.17% | 111B | |
+1.10% | 64.16B | |
+18.28% | 54.1B | |
+5.82% | 51.41B | |
+10.38% | 45.32B | |
+5.19% | 37.32B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Cantor Fitzgerald Starts Coverage on NeuroPace with Overweight Rating, $11 Price Target